Robin Von Rotz
PhD candidate and psychologist at the University Hospital of Psychiatry Zurich / University of Zurich
Data updated
Research Footprint
Robin Von Rotz appears in 6 tracked papers (2023–2025), most studied alongside Psilocybin, DMT and Ayahuasca, across Healthy Volunteers, Medicinal Chemistry & Drug Development and Safety & Risk Management.
Most-cited paper: TMS-EEG and resting-state EEG applied to Altered States of Consciousness: Oscillations, Complexity, and Phenomenology (45 citations).
Frequent co-authors: Erich Seifritz, Milan Scheidegger and Dominik Dornbierer.
Background & Research
Robin von Rotz is a psychologist by training with expertise in psychopharmacology. His work spans clinical pathology, EEG/fMRI neuroimaging, neurobiology, sleep research, and machine-learning-based modeling, and he is currently involved in psychedelic treatment research and clinical trial operations at the University of Zurich. He also appears as a co-author on studies of psilocybin for depression and alcohol use disorder, as well as DMT/harmine pharmacology trials.
Key Impact
He is a co-author on multiple clinical psychedelic studies spanning psilocybin, DMT/harmine, and EEG/TMS-EEG research, contributing to the growing evidence base for psychedelic-assisted psychiatry.
Collaboration Network
16 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Robin Von Rotz is associated with.
Psychiatric University Hospital, Zurich
The Psychiatric University Hospital Zurich (PUK) is affiliated with the University of Zurich and home to Franz Vollenweider's pioneering psychedelic neuroscience group, active since the 1990s; research includes PET imaging with psilocybin, S- and R-ketamine, MDMA, and DMT+harmine formulations, including a completed 2023 RCT of psilocybin (0.215 mg/kg) vs. placebo for major depressive disorder.
View stakeholder →Reconnect Labs
Private BiotechReconnect Labs AG is a Swiss clinical-stage company and University of Zurich spin-off developing precision psychopharmacology therapeutics, including sublingual DMT/harmine, sublingual 5-MeO-DMT, and sublingual dexmedetomidine. Founded in 2021 by Dr. Davor Kosanic (CEO) and co-founders from the Psychiatric University Clinic Zurich and ETH Zurich, building on ~30 years of in-human psychedelic research. The company raised CHF 22M+ (CHF 12M equity across Seed 2021 and Series A 2023–2025; CHF 10M in competitive grants from investors including Esperante Ventures, Lionheart Ventures, Negev Capital, and Noetic Fund) before emerging from stealth in August 2025. Their microcarrier-based transmucosal delivery platform (exclusively licensed) dramatically reduces inter-subject PK variability for DMT/harmine vs. oral ayahuasca and eliminates vomiting. RE03 (sublingual dexmedetomidine for insomnia in PTSD) is the most advanced programme with Swissmedic approval and FDA accelerated pathway confirmed.
View stakeholder →University of Zurich
academicWithin the 'Department of Psychiatry, Psychotherapy and Psychosomatics' at the University of Zurich, Dr Milan Scheidegger is leading a team conducting psychedelic research and therapy development. Researchers here are investigating the therapeutic potential of psychedelics to reverse maladaptive neurobehavioral patterns in stress-related mood disorders and to enhance psychotherapeutic learning capabilities.
View stakeholder →